Targets › TEK
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2030.
Tyrosine-protein kinase that acts as a cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of pro-inflammatory plasma proteins and leukocytes from blood vessels. (UniProt, Q02763)
Open in Phaseline: the race on TEK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| QuantumLeap Healthcare Collaborative | AMG 386 (Trebananib) Angiopoietin-1/2 receptor (Tie2) inhibitor | TEK | Phase 2 | Breast Neoplasms | Dec 2030 |
Breast Neoplasms (1)
mixed (1)
QuantumLeap Healthcare Collaborative (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.